Skip to main content
Full access
Letters
Published Online: 1 January 2014

Control of Mania With Chelation-Only in a Case of Wilson’s Disease

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Psychiatric symptoms are not uncommon in Wilson’s disease (WD). Some patients may present only with psychiatric symptoms in the initial phase of disease, but, in the majority, they develop in the course of WD along with neurological signs. The common psychiatric symptoms are incongruous behavior, irritability, depression, and cognitive impairment.1 There are also case reports of manic-like presentation in patients with WD.2,3 Management of manic symptoms in the previous case reports was done by mood stabilizers (mostly lithium or valproate), atypical antipsychotics, or ECT.3 We have not found any report of treatment of psychiatric symptoms only by optimization of copper chelation.

Case Report

A 19-year-old male patient with mild developmental intellectual impairment, with nil contributory family history of mental illness and no personal history of substance abuse, presented to the psychiatry outpatient department (OPD) of R. G. Kar Medical College, Kolkata, with a syndromal manic state for 2 weeks. He was a diagnosed case of WD, starting at age around age 14 with movement disorder, and this was under control on penicillamine 250 mg 3 times daily for the last 4 years. The patient was off medication for 2 months before current presentation and had no worsening of motor symptoms other than abnormal behaviors. Before the current presentation, he had no convulsion, head injury, high fever, vomiting, or jaundice. In the OPD, he was diagnosed as organic manic disorder4 and was prescribed olanzapine 10 mg once daily, sodium valproate 200 mg 3 times daily, along with penicillamine in the previous dosage. The patient went home without buying penicillamine and continued only psychotropics, which were provided free of cost from the hospital. The patient came back to the OPD within a week with gross extrapyramidal symptoms and uncontrolled mania. The patient was admitted and put on intravenous fluid with injectable lorazepam 4 mg twice daily, with omission of previous psychotropics and addition of penicillamine 250 mg/3 times daily. Screening of blood count, sugar, electrolytes, creatinine, liver function test, creatine phosphokinase, CT brain scan, and EEG were within normal limits. His extrapyramidal symptoms recovered in the next few days. He was continued only on penicillamine with tapering dose of oral lorazepam, and zinc was added by neurologists. The patient’s manic symptoms started resolving without adding any other psychotropics and were remitted by the next 4 weeks. Over next 1-year follow-up, the patient was maintained only on penicillamine and zinc and was free from both mental and physical symptoms of WD.
In this case, psychiatric manifestations appeared in the course of WD without any worsening of motor manifestations, which is quite rare.1 Emergence of manic symptoms on omission of penicillamine and remission after reinstitution confirms it to be a primary neuropsychiatric manifestation of WD. This case also signifies that only optimization of primary management with chelating agents may suffice for controlling psychiatric manifestations in WD. This agrees well with the concept of organic psychosis.4 This is important to reduce unnecessary health costs and the burden of side effects of psychotropics5 in these cases.

References

1.
Dening TR, Berrios GE: Wilson’s disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 1990; 28:255–265
2.
Machado AC, Deguti MM, Caixeta L, et al.: Mania as the first manifestation of Wilson’s disease. Bipolar Disord 2008; 10:447–450
3.
Loganathan S, Nayak R, Sinha S, et al.: Treating mania in Wilson’s disease with lithium. J Neuropsychiatry Clin Neurosci 2008; 20:487–489
4.
WHO: International Classification of Diseases 10th Revision Clinical Description and Diagnostic Guidelines. Geneva, World Health Organization, 1992
5.
Chroni E, Lekka NP, Tsibri E, et al.: Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13:531–532

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E06
PubMed: 24515687

History

Published online: 1 January 2014
Published in print: Winter 2014

Authors

Details

Saikat Mitra, M.B.B.S.
Dept. of PsychiatryR. G. Kar Medical CollegeKolkata, India
Anindya Kumar Ray, M.D.
Dept. of PsychiatryR. G. Kar Medical CollegeKolkata, India
Sanchari Roy, M.D.
Dept. of PsychiatryR. G. Kar Medical CollegeKolkata, India

Notes

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share